FINANCE/FUNDING ARTICLES

• Market Dislocations And Their Impact On Life Sciences Debt Financing

  : Life sciences companies seeking debt financing or facing challenges in their existing debt financing now face a very different financing environment. But there are some steps you can take.

• What Life Sciences Startups Can Do About Market Swings

  Ongoing capital needs that can span a decade or more mean that life sciences companies need the ability to navigate every season of market conditions. This requires strategic and long-term planning — and possibly some out-of-the-box thinking to ensure consistent funding well into the future.

• Ways To Face New Bio Funding & Banking Risks

  Funding bio startups has never been easy, but no doubt it just got harder. We wanted to find at least one company to talk about how it is handling the damage and aftermath of recent bank closures and other cash crunches, and we actually found two.

• Key Questions To Ask When Entering A Pharma Partnership

  Before entering a partnership, executives need to ask themselves and their prospective partners’ key questions in the following five areas:

• Explaining Private Equity’s Increased Appetite For Drug Development

  In recent years, private equity firms have shown a growing interest in pharmaceutical drug development. So, why is private equity making investments that resemble those of VC firms?

• A Recipe For Start-Up Success With A Platform Technology

  Platform companies face a fundamental problem — how to return money to investors in a reasonable time frame and simultaneously realize the appropriate value for their platform. Here’s one approach that worked.

• Anatomy Of A Biopharma VC Deal

  Ray Therapeutics CEO Paul Bresge and 4BIO Capital Managing Partner Dmitri Kuzmin, Ph.D. break down the deal that launched Ray and ponder the risk of a mission-driven biopharma CEO.

• Will The Finance And Funding Pendulum Swing Back To Black In 2023?

  Our experts talk about everything from alternative financing arrangements to investment trends that biopharma execs should keep their eyes on.

• Aristea CEO Talks Rare Disease Endpoints And Parallel Fundraising

  The CEO Of Aristea talks about the company’s unusual move to do both a series B round, but not as a crossover, while also making a deal with another pharma company.

• 5 Steps To Avoid Mismanaging Biopharma Grant Funds

  Here’s how to ensure you’re successfully maximizing that infusion of money and setting yourself up for further success in the grant world.